Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Why DuPont chose joint-venture

Executive Summary

DuPont explained its rationale for the sale in a Sept. 11 presentation to New York analysts. "The problem is we didn't have the marketing expertise or the ability to get the things through regulatory systems around the world. We didn't have a strong system. The choice was either sell the business, make a big acquisition or find an alliance. And our conclusion was we could maximize stock holder value by not making a big acquisition and all the risk that goes with that. We did not think that we could sell the business for any significant pay off for the shareholders and we were just very thrilled that we were able to entice Merck, who we consider the outstanding pharmaceutical company in the world".



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts